Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 107

Results For "Risk"

1561 News Found

Cardiac Surgeons call for lifestyle and dietary changes on World Heart Day
Healthcare | September 28, 2022

Cardiac Surgeons call for lifestyle and dietary changes on World Heart Day

There are certain foods can influence blood pressure, triglycerides, cholesterol levels and inflammation, all of which are risk factors for heart disease.


Mylab receives approval for HPV RT-PCR test for cervical cancers
Clinical Trials | September 28, 2022

Mylab receives approval for HPV RT-PCR test for cervical cancers

‘PathoDetect HPV Detection Test’ detects and discriminates the presence of high-risk HPV strains including 16 and 18 which cause most of the cervical cancers.


Novartis unveils new focused strategy
News | September 27, 2022

Novartis unveils new focused strategy

Transformation to pure-play Innovative Medicines company nears completion


Aptar Pharma collaborates with Fluidda
News | September 25, 2022

Aptar Pharma collaborates with Fluidda

The companies will leverage their respective proprietary technology platforms


JB Pharma rolls out its campaign #Heart2HeartChallengeIndia
Healthcare | September 24, 2022

JB Pharma rolls out its campaign #Heart2HeartChallengeIndia

The #Heart2HeartChallengeIndia campaign is very simple – you have to climb 60 steps in a minute, make a video of it, share it on your social media, tag 5 people, inviting them to take this challenge to check their heart health


Madhavbaug plans to foray in UAE, Europe & US
Healthcare | September 24, 2022

Madhavbaug plans to foray in UAE, Europe & US

To set up 50 lifestyle modification centres across the UAE in the next 24 months


BridgeBio Pharma, Sentynl Therapeutics receive marketing authorization in the EU for fosdenopterin
Drug Approval | September 22, 2022

BridgeBio Pharma, Sentynl Therapeutics receive marketing authorization in the EU for fosdenopterin

NULIBRY is a first-in-class cPMP substrate replacement therapy to reduce the risk of mortality in patients with MoCD Type A.


Evusheld long-acting antibody combination approved in the EU for the treatment of COVID-19
Drug Approval | September 21, 2022

Evusheld long-acting antibody combination approved in the EU for the treatment of COVID-19

Evusheld significantly reduced risk of severe COVID-19 or death in TACKLE Phase III treatment trial


Tezspire approved in the EU for the treatment of severe asthma
Drug Approval | September 21, 2022

Tezspire approved in the EU for the treatment of severe asthma

First and only biologic approved in the EU in patients with severe asthma with no phenotype or biomarker limitations


Quinten Health closes its financing round to advance disease modeling platforms
News | September 21, 2022

Quinten Health closes its financing round to advance disease modeling platforms

Quinten Health will announce in the coming months strategic partnerships with big pharma companies and data owners to launch the first disease modeling platforms.